Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Atossa Genetics (NASDAQ:ATOS), indicating concerns over the company's stock performance.
• Ascendiant Capital Markets has updated its price target for Atossa Genetics from $7.50 to $7.75 and has given the stock a "buy" rating.
• Atossa Genetics’ stock has a month-to-date high of $1.66 and a current consensus rating of "Moderate Buy" with an average price target of $6.25.

Atossa Genetics (NASDAQ:ATOS - Get Free Report)'s stock had its "sell (d-)" rating restated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Ascendiant Capital Markets increased their price objective on shares of Atossa Genetics from $7.50 to $7.75 and gave the company a "buy" rating in a research note on Monday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $6.25.

Atossa Genetics Price Performance

Shares of NASDAQ ATOS traded up $0.10 on Wednesday, hitting $1.11. The company's stock had a trading volume of 4,118,758 shares, compared to its average volume of 852,640. Atossa Genetics has a 12-month low of $0.55 and a 12-month high of $1.66. The company has a market capitalization of $143.38 million, a price-to-earnings ratio of -4.83 and a beta of 1.11. The stock has a 50 day moving average of $0.82 and a 200-day moving average of $0.81.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Sell-side analysts expect that Atossa Genetics will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATOS. Millennium Management LLC bought a new position in Atossa Genetics during the 4th quarter worth approximately $28,000. Charles Schwab Investment Management Inc. lifted its stake in Atossa Genetics by 40.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock valued at $284,000 after buying an additional 120,934 shares in the last quarter. Nuveen LLC bought a new position in Atossa Genetics in the first quarter valued at approximately $115,000. Ameriprise Financial Inc. bought a new position in Atossa Genetics in the second quarter valued at approximately $2,468,000. Finally, Jane Street Group LLC bought a new position in Atossa Genetics in the second quarter valued at approximately $381,000. Institutional investors own 12.74% of the company's stock.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.